Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum 276
- Development stage
- Preclinical
- Lead developer
- Church & Dwight
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum 276 (Lp276) is a probiotic strain of Gram-positive bacteria belonging to the Lactiplantibacillus genus, developed by Arm & Hammer (Church & Dwight Co.). Selected from a microbial library for its superior anti-inflammatory properties, Lp276 is designed to maintain intestinal epithelial barrier function and modulate wound repair in the gut. It regulates the expression of inflammatory cytokines during immune stimulus and is characterized by its ability to survive the gastrointestinal environment, including resistance to low pH and bile salts. The strain is classified as Generally Recognized As Safe (GRAS) and is primarily targeted at reducing gut inflammation and supporting immune system health in both human and animal applications.
- Other names
- Lp276Lp-276Lp 276Lactiplantibacillus plantarum 276
02
Targets
IL10 (Interleukin-10)
Beyond the preview
Go deeper on lactobacillus plantarum 276.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum 276.